Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | DDX3X | O00571 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 5/20 | 0.32 |
| ▸ | F2 | P00734 | 3/20 | 0.32 |
| ▸ | F10 | P00742 | 3/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.32 |
| ▸ | F7 | P08709 | 3/20 | 0.32 |
| ▸ | F3 | P13726 | 3/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10096706 | 1.00 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL10096715 | 0.98 | MAPK8 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL10096704 | 0.97 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL12105902 | 0.97 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL12105906 | 0.97 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL12995115 | 0.96 | HRH3 (0.36) | S1PR3ACACBHRH3DYRK1A | |
| SCHEMBL12994593 | 0.96 | HRH3 (0.36) | S1PR3ACACBHRH3DYRK1A | |
| SCHEMBL10096713 | 0.96 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL12995602 | 0.96 | S1PR3 (0.36) | S1PR3SOS1MAPK8MAPK9DDX3X | |
| SCHEMBL13198938 | 0.94 | HRH3 (0.36) | S1PR3ACACBHRH3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | S1PR3 1968/4885SOS1 4297/4885MAPK8 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.